摘要
溃疡性结肠炎(UC)现代治疗目标是尽早控制发作,不用激素的维持缓解、内镜下黏膜愈合,降低住院率与手术率,以提高生活质量。治疗原则是分级、分期、分段用药,采用综合性、个体化治疗措施。药物以氨基水杨酸类药物(5-ASA)、肾上腺皮质激素(GCS)和免疫抑制剂(IS)为主,新型生物制剂英夫利昔(IFX)用于顽固性UC与重症病例。手术指征为大出血、穿孔、中毒性巨结肠、恶变和内科治疗无效的顽固病例。中药用于80%的UC病例,深入研制和应用可起到更好的补充与替代作用。
Current goals of ulcerative colitis treatment include rapid remission, steroid-sparing remission, endoscopic mucosal healing, reduction in hospitalization and surgery and improvement in quality of life. The treat- ment principle is rational medications according to the severity, activity and extent of the disease with individual- ized and comprehensive treatment. The medications conventionally used are 5-ASA, GCS and IS. Newly developed biological agents like Anti TNF-α （ infliximab ） are used in severe UC and refractory cases. Traditional Chinese Medicines have been used in more than 80% of UC cases and will play a great role in the future. The indications for surgery include acute perforation, massive hemorrhage, toxic megacolon, malignancy and refractory cases for medical therapy.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2010年第4期383-385,共3页
Chinese Journal of Practical Internal Medicine
关键词
溃疡性结肠炎
传统治疗
生物治疗
ulcerative colitis
conventional therapy
biological therapy
